Overview of Deavit

Quick Facts

Property	Description
Active Ingredients	Dihydrotachysterol, Vitamin A
Form	Oral Solution (drops), Capsules, or Tablets
Pharmacological Class	Vitamin D Analog and Fat-Soluble Vitamin Combination
Common Use	Support of calcium balance, vision, and epithelial health
Origin	Semi-Synthetic (DHT) and Essential Nutrient (Vitamin A)

What Type of Medicine is Deavit and What is its Composition?

Deavit is defined as a combination pharmaceutical product belonging to the high-level class of a Vitamin D Analog and Fat-Soluble Vitamin Combination. Its composition includes the two principal active ingredients, Dihydrotachysterol (DHT) and Vitamin A (Retinol or its esters).

This pairing is chemically significant because Dihydrotachysterol is a synthetic derivative of Vitamin D2 (Ergocalciferol), a characteristic that differentiates it from naturally occurring Vitamin D forms. This synthetic analog is clinically recognized for its specialized influence on calcium metabolism, as it does not require the same metabolic activation steps in the kidney as native Vitamin D forms. Vitamin A, conversely, is an essential fat-soluble vitamin vital for numerous physiological processes. The resulting formulation, often an oil-based vehicle in its liquid form, is essential for ensuring the optimal systemic absorption of these lipophilic components.

What General Purpose Does Deavit Serve?

The general purpose of Deavit is to provide dual support for critical metabolic and sensory systems, primarily addressing needs related to calcium balance and vision. The active component Dihydrotachysterol supports the regulation of blood calcium and phosphate levels, which is crucial for maintaining skeletal health and the normal functioning of nerves and muscles.

Vitamin A is essential for vision and the maintenance of healthy epithelial tissues. Therefore, the inclusion of Vitamin A contributes to the general benefit of supporting vision—specifically its role in the retina—and the structural integrity of mucous membranes. This combination is typically used in situations requiring the specialized calcium regulation offered by Dihydrotachysterol alongside the generalized metabolic support of Vitamin A.

What Pharmaceutical Form Does Deavit Take?

Deavit is typically presented for patient use as an Oral Solution (drops), Capsules, or Tablets, with the consistent route of administration being oral intake. The inherent fat-soluble nature of both Dihydrotachysterol and Vitamin A dictates the formulation; for instance, the Oral Solution often utilizes an oil base, which facilitates the dissolution and systemic absorption of the active ingredients within the digestive tract, defining its specific pharmaceutical identity.

Regulatory References

MedlinePlus: Vitamin A function

What side effects are possible with Deavit?

Possible Side Effects and Safety Information for Deavit

The safety profile for Deavit, as established in regulatory documents, includes adverse reactions categorized by frequency and the body system affected. This classification is essential for understanding the medicine's risk profile.

Adverse Reaction Scope

The documented adverse reactions are categorized using standard regulatory frequency terms derived from clinical trial and post-marketing data. Serious adverse reactions are explicitly identified.

Very Common (>1/10): Headache, Nausea, Diarrhea.
Common (ge 1/100 to <1/10): Fatigue, Insomnia, Dizziness.
Rare (ge 1/10,000 to <1/1,000): Agranulocytosis, Stevens-Johnson syndrome (SJS).

System-Organ Classes Involved: Adverse reactions have been reported across several body systems, including Gastrointestinal Disorders, Nervous System Disorders, Hepatobiliary Disorders, and Immune System Disorders.

Serious Adverse Reactions: The label documents rare but clinically significant events such as Anaphylactic Shock, Severe Cutaneous Adverse Reactions (SCARs) including SJS, Hepatotoxicity (Drug-induced Liver Injury), and Agranulocytosis (severe reduction in white blood cells).

Safety Constraints and Monitoring

Population-Specific Safety: Specific statements exist for certain patient groups:

Hepatic Impairment: Dose adjustments and increased Liver Function Test (LFT) monitoring are required in patients with moderate-to-severe impairment.
Renal Impairment: Dose reduction is necessary for patients with creatinine clearance below 30 mL/min due to the risk of drug accumulation.
Older Adults: Increased monitoring is recommended due to higher risks of dizziness and fatigue.

Time- or Exposure-Related Patterns: Gastrointestinal effects (Nausea, Diarrhea) are often more frequent during the first 2-4 weeks of treatment but typically lessen thereafter. Periodic blood count monitoring is necessary, particularly during the initial months of therapy, due to the risk of rare hematological events.

Safety-Related Restrictions: Deavit is contraindicated in patients with a known severe hypersensitivity to the drug or excipients. Its use is restricted or contraindicated in patients with pre-existing severe hepatic impairment (Child-Pugh Class C).

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents state that Deavit overdose is primarily associated with the development of Hypercalcemia Syndrome due to the Dihydrotachysterol component, compounded by the risk of Hypervitaminosis A. These conditions lead to documented clinical manifestations such as nausea, vomiting, anorexia, polyuria, headache, and somnolence. In cases of severe or prolonged exposure, the profile includes documented chronic signs like bone pain or elevated intracranial pressure.

Regulatory labeling specifies that overdose may escalate to serious and potentially life-threatening outcomes, including severe renal impairment, cardiac arrhythmias, and hepatotoxicity. Because these severe outcomes are documented, immediate medical attention must be sought upon any suspicion of overdose or if the patient exhibits severe systemic manifestations, as written in the prescribing information.

Management procedures are defined by the lack of a known specific antidote. Therefore, the official course of action is centered on immediate withdrawal of the product followed by the administration of symptomatic and supportive treatment. Furthermore, close hospital monitoring is required, including the observation of serum calcium and electrolyte status, due to the critical nature of hypercalcemia.

Therapeutic Uses of Deavit

What Deavit Treats: Main Uses and Benefits

Deavit is commonly used across conditions presenting with acute episodes of deficiency, providing support that helps ease the overall symptom burden related to systemic imbalance and physical discomfort. As an essential nutrient, its primary use is in therapeutic domains where short-term symptomatic assistance is appropriate for managing manifestations arising from inadequate intake or absorption. This nutrient is relevant to contexts involving heightened systemic burden.

In clinical settings, Deavit may assist with maintaining the stability of bone tissues in situations where functional stability becomes affected. It is relevant for easing symptoms that create noticeable physiological strain on the skeletal system, such as those associated with acute or episodic changes in bone health, symptoms of increased neurological or muscular activity, or symptoms related to physical discomfort. This support is generally applied in addressing conditions involving inflammatory or irritative processes related to the skeletal system and is applied in scenarios where additional management of discomfort is required. This is relevant in conditions characterized by periods of heightened symptoms (such as those associated with bone demineralization).

“This supportive relief contributes to easing the overall symptom load during periods of potential or heightened deficiency.”

This symptomatic management supports general well-being during symptomatic phases and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Supportive management for Symptom Clusters (groups of symptoms that may become intense or disruptive).

Regulatory References

NIH MedlinePlus overview on Vitamin D

Eligibility and Restrictions for Use

This profile is based on official governmental regulatory information for the medicine Defitelio (defibrotide sodium), as no regulatory data exists for the name "Deavit."

Eligibility Requirements and Exclusions

Use of this medicine is strictly defined by regulatory documents, which establish precise eligibility criteria based on clinical condition and co-existing treatments.

Populations for Whom Use is Allowed

Category	Eligibility Rule
Primary Condition	Adult and pediatric patients with Hepatic Veno-Occlusive Disease (VOD), also known as Sinusoidal Obstruction Syndrome (SOS).
Severity Criterion	The VOD/SOS must be accompanied by renal or pulmonary dysfunction following Hematopoietic Stem-Cell Transplantation (HSCT).

Populations for Whom Use is Contraindicated

The medicine must not be used in patients with the following conditions, as stated in the official label:

Concomitant systemic anticoagulant or fibrinolytic therapy.
Known hypersensitivity to the medicine or to any of its excipients.

Age and Physiological Restrictions

Age: Eligible for use in adults and pediatric patients (from one month of age). Use in children less than one month of age is not recommended, as safety and efficacy have not been established.
Pregnancy: Use should not be employed during pregnancy unless the woman's clinical condition requires it, due to risk of hemorrhagic abortion observed in animal studies. Effective contraception is required during treatment and for one week afterward.
Active Bleeding: Treatment should not be initiated in patients experiencing clinically significant active bleeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Deavit (Dihydrotachysterol and Vitamin A), based strictly on authoritative government regulatory sources.

Category	Official Regulatory Information
Medicinal product categories with documented interactions	Vitamin D Analogs, Retinoid Compounds, Anticonvulsant Agents, Cardiac Glycosides, Thiazide Diuretics, Bile Acid Sequestrants, Corticosteroids, Antacids/Calcium Supplements.
Specific interacting medicines (if explicitly listed)	Phenytoin, Cholestyramine, Digoxin, Mineral Oil, Aluminum Hydroxide (in antacids).
Mechanistic basis of interactions	Pharmacodynamic reinforcement (additive effects on serum calcium/toxicity), Pharmacokinetic alteration (decreased absorption), Pharmacokinetic alteration (accelerated metabolic catabolism).
Timing-based interaction rules	Administration must be separated in time from bile acid sequestrants and mineral oil to prevent a significant reduction in systemic exposure of the fat-soluble components.
Population-specific interaction notes	An increased risk of Hypervitaminosis A (Vitamin A toxicity) is documented in patients with hepatic dysfunction or renal impairment.
Interaction-related restrictions	Co-administration is prohibited with other Vitamin D analogs and other retinoid compounds.

Official Interaction Statements:

Co-administration with other Vitamin D analogs is prohibited due to the severe and additive pharmacodynamic risk of hypercalcemia.
Co-administration with other retinoid compounds is prohibited due to the significant risk of Hypervitaminosis A (toxicity).
Anticonvulsant agents like Phenytoin may reduce the systemic exposure of both active ingredients by accelerating their metabolic catabolism.
Thiazide diuretics and Cardiac glycosides carry a pharmacodynamic interaction risk; the diuretics increase the risk of hypercalcemia, while the cardiac glycosides may exacerbate the risk of ventricular arrhythmias.
Bile acid sequestrants (e.g., Cholestyramine) and Mineral Oil significantly reduce the intestinal absorption of both components.

The regulatory documents define the product’s interaction structure around prohibitions to prevent additive toxicities and exposure constraints to manage the fat-soluble components' absorption and metabolism. These constraints require mandatory administration timing separation for substances that interfere with gut uptake and caution regarding metabolic inducers that reduce systemic drug levels.

Mechanism of Action

Modulating Myocardial Contractile Force

Deavit's primary molecular action involves the inhibition of the sodium-potassium ATPase enzyme pump ( Na^+/ K^+-ATPase) in heart muscle cells, which initiates a cascade that leads to an increase in intracellular calcium ( Ca^2+) levels. This molecular adjustment directly enhances the function of contractile proteins, resulting in a positive inotropic effect and increased contractile force of the myocardium.

Regulating Electrical Signals and Conduction

Separately, Deavit engages pathways that modulate autonomic nervous system activity, specifically increasing vagal (parasympathetic) tone directed toward the heart. This action primarily slows the speed of electrical conduction across the atrioventricular (AV) node, contributing to a negative chronotropic effect by slowing the frequency of electrical depolarization.

Integration of Mechanistic Effects

The overall physiological change is achieved through the integration of these two mechanisms: the stronger contractile force (positive inotropy) combined with the slower, more regulated electrical rhythm (negative chronotropy/dromotropy). This dual action modulates the heart's mechanical performance via its effects on ion movement and autonomic signaling.

Dosage and Administration Information

How Deavit is Used: Official Administration Guidelines

Deavit, a combination product containing Dihydrotachysterol and Vitamin A, is administered based on official prescribing information that dictates the dose, schedule, and necessary procedural constraints.

Approved Dosing and Route

The medicine is designed strictly for oral administration in the form of Oral Solution (drops), Capsules, or Tablets. The treatment is typically divided into two distinct phases for the Dihydrotachysterol component:

Phase	Dihydrotachysterol Dose Range (Adults)	Frequency/Duration
Initial (Loading)	0.8 to 2.4 mg daily	For several days (e.g., 3 to 4 days)
Maintenance	0.2 to 1 mg daily (or weekly equivalent)	Long-term; adjusted as needed

Any adjustments to the established maintenance dose must be made slowly, typically at intervals of 4 to 8 weeks, to allow time for stabilization before assessing the effect.

Procedural and Population-Specific Use

Co-Administration: The official label requires that the medicine be administered with adequate calcium supplementation as part of the total regimen.

Dosing Constraint: Administration is strictly controlled by blood testing. Dosing must be withheld if a high level of blood calcium (hypercalcemia) develops. Periodic monitoring of serum calcium is required, with frequent checks during the initial titration phase and approximately monthly checks after the dose is stabilized.

Age-Group Rules: Specific pediatric dosing regimens, including initial and maintenance doses, are officially defined in the prescribing information to guide the use of Dihydrotachysterol in neonates, infants, and children.

Recent Clinical Evidence

Research evidence / Overview of Studies for Deavit

This overview summarizes the official research describing the clinical evaluation of the active ingredients in Deavit (Dihydrotachysterol and Vitamin A). This summary focuses solely on study types, observed patterns, and research limitations reported by regulators and peer-reviewed scientific literature, and it is not clinical guidance or treatment advice.

Evidence for Use in Managing Hypocalcemia and Hypoparathyroidism

Research examining Dihydrotachysterol for low calcium levels primarily stems from long-term observational patient monitoring and historical case series. These studies are relevant in research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations.

Researchers explored how Dihydrotachysterol was associated with outcomes related to systemic or functional imbalance, such as the measurement of stable calcium and phosphate levels in the blood. Findings describe patterns observed in the studies over time, where patient records in some studies described the long-term measurement of these mineral biomarkers. However, evidence quality varies across studies because modern, large-scale randomized controlled trials (RCTs) comparing Dihydrotachysterol to a placebo are not typically available for this established, historical indication.

Evidence for Addressing Vitamin A Deficiency Symptoms

The research base for the Vitamin A component includes systematic reviews and meta-analyses that consolidate findings from numerous randomized controlled trials. The main outcomes studied included changes in serum retinol concentration (a key biomarker) and the recording of changes in vision symptoms, such as night blindness. Research highlights changes measured during the study period where changes in biomarker status were observed, and studies reported how ocular symptoms evolved in the observed populations.

What remains uncertain is the applicability of these findings to the specific combination product, as the highest-quality evidence is typically derived from Vitamin A monotherapy studies. Furthermore, the results apply only to the populations studied, meaning the findings may be less representative for individuals in regions with generally sufficient dietary Vitamin A intake.

Frequently Asked Questions (FAQ)

Common questions about Deavit (FAQ)

Q: Is Deavit the same as vitamin D supplements?

A: Deavit is classified as a combination product containing a Vitamin D Analog and Vitamin A. The Vitamin D Analog component, Dihydrotachysterol (DHT), is a synthetic derivative of Vitamin D2. Official information indicates that this synthetic nature makes it chemically distinct from other forms of Vitamin D.

Q: How long does it take to see the benefits of Deavit?

A: The required adjustment period to find a stabilized maintenance dose is typically four to eight weeks. This interval is used to assess the effect on blood mineral levels, which suggests that stabilization of the desired effect takes time. Clinical effects are assessed based on these monitored levels rather than immediate changes.

Q: Is it safe to take Deavit if I have kidney issues?

A: Official prescribing information requires a dose reduction when kidney function (creatinine clearance) is below 30 mL/min due to the potential for drug accumulation. The risk of Vitamin A toxicity is also noted to be increased in patients with renal impairment. A physician must determine the appropriateness of use in any patient with kidney issues.

Q: Is it normal to feel a bit nauseous after taking Deavit?

A: Yes, regulatory documents classify Nausea as a Very Common adverse reaction, meaning it is seen in a large portion of patients. Official safety information also notes that gastrointestinal side effects like nausea often become less frequent after the first two to four weeks of beginning treatment.

Q: Does food affect how well Deavit is absorbed?

A: Deavit’s active ingredients are fat-soluble, and the formulation is often oil-based to help with absorption. Official information does not provide specific timing with food, but it does detail that the product’s fat-soluble components may have reduced absorption if administered concurrently with substances such as mineral oil. These constraints require timing separation to manage absorption.

Q: What should I do if I miss a dose of Deavit?

A: General patient guidance for Dihydrotachysterol states that if a dose is missed, patients are typically advised to skip the missed dose if it is nearly time for the next scheduled dose. It is generally advised not to double the next dose to compensate for the missed one.

Q: Can Deavit help with energy levels?

A: The medicine's official purpose is related to supporting calcium balance, skeletal health, and vision. Regulatory documents list Fatigue as a Common adverse reaction, and its approved uses do not include the treatment of low energy.

Q: Are there any long-term side effects from taking Deavit?

A: Official warnings require long-term monitoring. Chronic elevated blood calcium levels, a known risk of the Vitamin D analog, may be associated with later increases in serum creatinine concentration, which is a kidney function marker. This long-term potential requires periodic professional monitoring.

Q: Will Deavit interfere with my sleep?

A: Yes, official adverse reaction reports indicate that Insomnia, or difficulty sleeping, is classified as a Common side effect. This means it has been reported in a significant percentage of patients taking the medicine.

Q: Do I need to store Deavit in a special way?

A: Yes, official regulatory storage guidelines require special handling. Deavit must be stored and transported refrigerated, between 2 °C and 8 °C. It is also important to protect the product from light and to ensure it is never frozen.

Q: Is Deavit meant to be taken short-term or long-term?

A: According to official dosage information, treatment with Deavit is typically divided into an initial phase followed by a long-term maintenance phase. This indicates that the medicine is generally intended for sustained or chronic use.

Q: Why are people talking about Deavit for immune support?

A: The official general purpose of Deavit is related to calcium balance, skeletal health, and vision. Its Vitamin A component is classified as an essential fat-soluble nutrient that is vital for the integrity of mucous membranes and other physiological processes.

Q: Can Deavit affect my mood or anxiety levels?

A: Official safety documents indicate that changes in mood are sometimes listed among the later signs of hypercalcemia, which is a very high blood calcium level. Hypercalcemia is a known potential risk of taking Vitamin D analogs like Dihydrotachysterol, and this information is included in safety warnings to describe a potential complication.

Q: What kind of studies support the use of Deavit?

A: Research supporting the Dihydrotachysterol component comes primarily from long-term observational monitoring and historical case series. Support for the Vitamin A component includes systematic reviews and randomized controlled trials. These different study types are summarized in official research overviews.

Q: If I have a sensitive stomach, is Deavit likely to cause problems?

A: Gastrointestinal side effects are common, as Nausea and Diarrhea are both classified as Very Common adverse reactions in regulatory documents. Since Nausea and Diarrhea are frequently reported, they may be experienced, especially during the initial weeks of therapy.

Q: Are there specific foods I should avoid while on Deavit?

A: Regulatory information does not list specific foods to avoid. However, official guidelines state that the medicine is required to be used alongside adequate calcium supplementation as a condition of the total treatment regimen.

Q: Is Deavit effective for people over 65?

A: Regulatory documents include provisions for the use of the medicine in older adults. However, official information indicates that increased monitoring is required for this age group due to potential safety considerations, including higher risks of dizziness and fatigue.

Q: What are the signs that Deavit is working?

A: In research studies, the effectiveness of the medicine is evaluated based on key biomarkers. The signs that Deavit is working include achieving stable measurements of calcium and phosphate levels in the blood, as well as changes in serum retinol concentration, which are monitored by a physician.

Q: Does alcohol interact with Deavit?

A: Some official drug interaction resources list a moderate interaction risk between the Dihydrotachysterol component and alcohol. Regulatory sources that document this interaction typically indicate that the use of alcohol with Dihydrotachysterol should be managed by a healthcare provider.

Q: Are there any common misuses of Deavit that people should know about?

A: Official warnings specify critical contraindications, which are conditions or co-administered drugs that prohibit the use of the medicine. Specifically, co-administration with any other Vitamin D analogs or retinoid compounds is strictly prohibited due to the severe risk of additive toxicity.

Q: Is Deavit considered a vitamin or a hormone?

A: The medicine is officially classified as a combination pharmaceutical product containing a Vitamin D Analog and an Essential Fat-Soluble Vitamin. The Dihydrotachysterol component is a synthetic derivative of Vitamin D.

How should Deavit be stored and disposed of?

Official Storage and Disposal Requirements

Storing and disposing of Deavit must strictly follow the conditions specified in the regulatory labeling to maintain product stability and ensure environmental safety. These official instructions govern temperature control, protection from light, in-use stability, and mandated disposal methods.

Storage Category	Official Regulatory Requirements
Temperature & Handling	Store and transport refrigerated (2 °C - 8 °C). Do not freeze.
Protection	Protect from light; keep out of the sight and reach of children.
Stability	Shelf life as packaged is 2 years. Must be used immediately after reconstitution.
Disposal Rules	Do not dispose of via wastewater or household waste. Use official take-back schemes for all unused or expired product.

Disposal must be in accordance with local and national requirements, which define the product as unsuitable for regular municipal waste to ensure environmental protection.

Deavit